Peramivir and laninamivir susceptibility of circulating influenza A and B viruses |
| |
| Authors: | Sook‐Kwan Leang Simon Kwok Sheena G. Sullivan Sebastian Maurer‐Stroh Anne Kelso Ian G. Barr Aeron C. Hurt |
| |
| Affiliation: | 1. WHO Collaborating Centre for Reference and Research on Influenza, , North Melbourne, Vic., Australia;2. Bioinformatics Institute (BII), Agency for Science, Technology and Research (A*STAR), , Singapore City, Singapore;3. School of Biological Sciences (SBS), Nanyang Technological University (NTU), , Singapore City, Singapore;4. National Public Health Laboratory (NPHL), Communicable Diseases Division, Ministry of Health (MOH), , Singapore City, Singapore;5. School of Applied Sciences and Engineering, Monash University, , Churchill, Vic., Australia |
| |
| Abstract: | ![]()
Influenza viruses collected from regions of Asia, Africa and Oceania between 2009 and 2012 were tested for their susceptibility to two new neuraminidase inhibitors, peramivir and laninamivir. All viruses tested had normal laninamivir inhibition. However, 3·2% (19/599) of A(H1N1)pdm09 viruses had highly reduced peramivir inhibition (due to H275Y NA mutation) and <1% (6/1238) of influenza B viruses had reduced or highly reduced peramivir inhibition, with single occurrence of variants containing I221T, A245T, K360E, A395E, D432G and a combined G145R+Y142H mutation. These data demonstrate that despite an increase in H275Y variants in 2011, there was no marked change in the frequency of peramivir‐ or laninamivir‐resistant variants following the market release of the drugs in Japan in 2010. |
| |
| Keywords: | Antiviral susceptibility laninamivir neuraminidase inhibitors peramivir |
|
|
